Trilaciclib Dihydrochloride Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as PHARMACOSMOS. It is marketed under 1 brand name, including COSELA. Available in 1 different strength, such as EQ 300MG BASE/VIAL, and administered through 1 route including POWDER;INTRAVENOUS.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"66711","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"e8b66101a98c4d05ba9a","publication_number":"US10189850B2","cleaned_patent_number":"10189850","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-25","publication_date":"2019-01-29","legal_status":"Granted"} US10189850B2 Formulation 29 Jan, 2019 Granted 25 Oct, 2031
{"application_id":"66649","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"e8b66101a98c4d05ba9a","publication_number":"US8598197B2","cleaned_patent_number":"8598197","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-25","publication_date":"2013-12-03","legal_status":"Granted"} US8598197B2 Molecular Formulation 03 Dec, 2013 Granted 25 Oct, 2031
{"application_id":"66701","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"e8b66101a98c4d05ba9a","publication_number":"US8598186B2","cleaned_patent_number":"8598186","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-25","publication_date":"2013-12-03","legal_status":"Granted"} US8598186B2 Molecular Formulation 03 Dec, 2013 Granted 25 Oct, 2031
{"application_id":"66714","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"e8b66101a98c4d05ba9a","publication_number":"US10927120B2","cleaned_patent_number":"10927120","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-25","publication_date":"2021-02-23","legal_status":"Granted"} US10927120B2 Formulation 23 Feb, 2021 Granted 25 Oct, 2031
{"application_id":"66710","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"e8b66101a98c4d05ba9a","publication_number":"US10189849B2","cleaned_patent_number":"10189849","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-25","publication_date":"2019-01-29","legal_status":"Granted"} US10189849B2 Molecular 29 Jan, 2019 Granted 25 Oct, 2031
{"application_id":"66634","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"16e6839dae7f4c67bb20","publication_number":"US11040042B2","cleaned_patent_number":"11040042","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-25","publication_date":"2021-06-22","legal_status":"Granted"} US11040042B2 Formulation 22 Jun, 2021 Granted 25 Oct, 2031
{"application_id":"66709","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"e8b66101a98c4d05ba9a","publication_number":"US9957276B2","cleaned_patent_number":"9957276","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-10-25","publication_date":"2018-05-01","legal_status":"Granted"} US9957276B2 Molecular 01 May, 2018 Granted 25 Oct, 2031
{"application_id":"66628","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"16e6839dae7f4c67bb20","publication_number":"US10085992B2","cleaned_patent_number":"10085992","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-03-14","publication_date":"2018-10-02","legal_status":"Granted"} US10085992B2 02 Oct, 2018 Granted 14 Mar, 2034
{"application_id":"66633","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"16e6839dae7f4c67bb20","publication_number":"US10966984B2","cleaned_patent_number":"10966984","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-03-14","publication_date":"2021-04-06","legal_status":"Granted"} US10966984B2 06 Apr, 2021 Granted 14 Mar, 2034
{"application_id":"66640","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"128ce33e1f974338bffc","publication_number":"US11717523B2","cleaned_patent_number":"11717523","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-03-14","publication_date":"2023-08-08","legal_status":"Granted"} US11717523B2 08 Aug, 2023 Granted 14 Mar, 2034
{"application_id":"66585","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"16e6839dae7f4c67bb20","publication_number":"US9487530B2","cleaned_patent_number":"9487530","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-03-14","publication_date":"2016-11-08","legal_status":"Granted"} US9487530B2 08 Nov, 2016 Granted 14 Mar, 2034
{"application_id":"110519","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"617567ea999743309fc7","publication_number":"US11529352B2","cleaned_patent_number":"11529352","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-23","publication_date":"2022-12-20","legal_status":"Granted"} US11529352B2 20 Dec, 2022 Granted 23 Jul, 2039
{"application_id":"139379","ingredient":"TRILACICLIB DIHYDROCHLORIDE","trade_name":"COSELA","family_id":"","publication_number":"US12168666B2","cleaned_patent_number":"12168666","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-11-13","publication_date":"2024-12-17","legal_status":"Patented Case"} US12168666B2 Molecular Formulation 17 Dec, 2024 Patented Case 13 Nov, 2040

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Trilaciclib Dihydrochloride

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.